Reaction
Central Obesity reporting signals
As of the last recalculation, Central Obesity appears in 723 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is RALTEGRAVIR (PRR 66.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Raltegravir | 36 | 66.0 | 66.1 |
| Ritonavir 100 Mg | 31 | 62.4 | 62.5 |
| Tofacitinib Citrate | 26 | 59.2 | 59.3 |
| Ritonavir | 44 | 46.1 | 46.2 |
| Desoximetasone | 28 | 44.0 | 44.0 |
| Darunavir | 22 | 43.2 | 43.2 |
| Mercaptopurine | 24 | 41.2 | 41.2 |
| Standardized Senna Concentrate | 17 | 39.8 | 39.9 |
| Relugolix | 23 | 29.0 | 29.0 |
| Dapsone | 10 | 27.3 | 27.4 |
| Daspone | 9 | 26.9 | 26.9 |
| Dapsone Gel, 5% | 9 | 26.9 | 26.9 |
| Zidovudine | 12 | 26.3 | 26.3 |
| Clobetasol Propionate Ointment Usp, 0.05% | 9 | 25.5 | 25.5 |
| Clobetasol Propionate | 9 | 25.4 | 25.4 |
| Magnesium Sulfate In Water For | 9 | 20.5 | 20.5 |
| Atazanavir | 10 | 20.3 | 20.3 |
| Lamivudine | 21 | 20.1 | 20.1 |
| Lamivudine Oral | 17 | 19.8 | 19.8 |
| Sumatriptan Succinate | 15 | 17.4 | 17.4 |
| Dexlansoprazole | 23 | 16.4 | 16.4 |
| Dolutegravir Sodium | 5 | 16.1 | 16.1 |
| Emtricitabine And Tenofovir Disoproxil Fumarate | 24 | 15.6 | 15.6 |
| Mepolizumab | 23 | 13.7 | 13.7 |
| Voclosporin | 4 | 13.3 | 13.3 |
| Patiromer | 6 | 12.6 | 12.6 |
| Abaloparatide | 8 | 7.9 | 7.9 |